A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder

BACKGROUND: Major depressive disorder (MDD) is a serious illness in children and adolescents. Vilazodone is a selective serotonin reuptake inhibitor approved for MDD in adults. This study evaluated the efficacy, safety, and tolerability of vilazodone in adolescent patients, ages 12–17 years, with MD...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgam, Suresh, Chen, Changzheng, Migliore, Raffaele, Prakash, Chandran, Edwards, John, Findling, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028869/
https://www.ncbi.nlm.nih.gov/pubmed/29633166
http://dx.doi.org/10.1007/s40272-018-0290-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028869/
https://www.ncbi.nlm.nih.gov/pubmed/29633166
http://dx.doi.org/10.1007/s40272-018-0290-4

Ejemplares similares